Burning Rock Biotech (BNR): which funds own it
A 13F shows the portfolio at quarter-end and is filed up to 45 days later: these are not real-time positions and they may have changed.
Sections with a free account
1 concentrated manager holds it; combined they have held more shares for 3 quarters in a row (0 added, 0 trimmed). Its median weight in those portfolios is 0.6%. 1 officer or director bought in 6 months.
Who owns Burning Rock Biotech?
Burning Rock Biotech trades in the U.S. through ADRs, certificates that represent shares of a non-U.S. company. Form 13F counts ADRs while the company reports ordinary shares, so we do not compute percentages. As of Jun 30, 2026, the largest ADR holders reported on Form 13F were Kynam Capital Management (1.2 million ADRs), Crcm (211,997 ADRs) and Renaissance Technologies (52,838 ADRs).
Which institutions hold the most Burning Rock Biotech shares?
Per Form 13F filings as of Jun 30, 2026, in ADRs:
- 1. Kynam Capital Management: 1.2 million ADRs
- 2. Crcm: 211,997 ADRs
- 3. Renaissance Technologies: 52,838 ADRs
- 4. Morgan Stanley: 43,594 ADRs
- 5. Sumitomo Mitsui Trust Group: 29,724 ADRs
- 6. Amova Asset Management Americas: 29,724 ADRs
- 7. Bank of America: 29,164 ADRs
- 8. Citadel Advisors: 27,288 ADRs
- 9. HSG Holding: 21,212 ADRs
- 10. UBS Group: 17,916 ADRs
Sources:All of the company's proxy statements on EDGAR ↗
We hold 13D and 13G filings made since Dec 23, 2024: a holder above 5% that has not filed since then does not appear here.
Burning Rock Biotech revenue
Burning Rock Biotech reported annual revenue of $77.2 million for fiscal year 2025 (year ended December 31, 2025), according to its Form 20-F filed with the SEC (XBRL data).
Quarter flow (concentrated managers)
Change in managers (1 → 1): 0 opened · 0 exited = 0
Net flow in the quarter: $0K (0 shares) · bought $0 and sold $0Shares concentrated managers added minus those they cut, valued at the 13F quarter-end implied price, not each trade's price. It is a different measure from the change in managers: the two can have opposite signs.
Accumulation: combined they have held more shares for 3 quarters in a row (0 added, 0 trimmed). It is the combined share count of those still holding it: one large buyer can outweigh many who trimmed.
Concentrated managers holding it
- Kynam Capital Management$10.5M0.6%
Up to 15, sorted by position value. The percentage is the weight in each manager's portfolio.
Largest holders of BNR (all 13F filers)
- Kynam Capital Managementconcentrated1.2 MInvestment firm+11 K
- Crcm212 KType not verified−70 K
- Renaissance Technologies53 KQuant or multi-manager+17 K
- Morgan Stanley44 KBank or trading desk+28 K
- Sumitomo Mitsui Trust Group30 KBank or trading desk−413
- Amova Asset Management Americas30 KType not verified−413
- Bank of America29 KBank or trading desk0
- Citadel Advisors27 KQuant or multi-manager+9,619
- HSG Holding21 KPrivate equity or venture capitalno data
- UBS Group18 KBank or trading desk+18 K
- Kynam Capital Managementconcentrated
- Shares
- 1.2 M
- Change
- +11 K
See more
- Type
- Investment firm
- Value
- $10.5M
- Crcm
- Shares
- 212 K
- Change
- −70 K
See more
- Type
- Type not verified
- Value
- $1.8M
- Shares
- 53 K
- Change
- +17 K
See more
- Type
- Quant or multi-manager
- Value
- $442K
- Shares
- 44 K
- Change
- +28 K
See more
- Type
- Bank or trading desk
- Value
- $365K
- Shares
- 30 K
- Change
- −413
See more
- Type
- Bank or trading desk
- Value
- $249K
- Shares
- 30 K
- Change
- −413
See more
- Type
- Type not verified
- Value
- $258K
- Shares
- 29 K
- Change
- 0
See more
- Type
- Bank or trading desk
- Value
- $244K
- Shares
- 27 K
- Change
- +9,619
See more
- Type
- Quant or multi-manager
- Value
- $237K
- Shares
- 21 K
- Change
- no data
See more
- Type
- Private equity or venture capital
- Value
- $178K
- Shares
- 18 K
- Change
- +18 K
See more
- Type
- Bank or trading desk
- Value
- $150K
The 10 13F filers with the most shares as of Jun 30, 2026, whatever their type (index firms usually come first). “Change”: shares added or cut versus the previous quarter, split-adjusted; “no data” = there is no comparable portfolio for the previous quarter (no filing, or a filing with its holdings under confidential treatment). “% of the company” only where shares outstanding are up to date. Entities of the same group file separately and some 13F filings include other managers: there may be double counting. With a free account: the top 25, the largest buyers and the largest sellers.
Fundamentals
12-month figures to Dec 31, 2025 · balance sheet as of Dec 31, 2025.
- Operating margin
- -10.2%
- Net margin
- -10.3%
- ROE
- -10.3%
- Revenue (TTM)
- $77.2M
- Revenue growth
- 9.2%
- Net income (TTM)
- $-7.9M
- Net debt / EBITDA
- —
- Free cash flow (TTM)
- $-4.8M
- Quality vs sector
- —
This company's sector comes from its SIC code, unreviewed, or has too few comparable companies: we do not compare it with its sector.
Figures from the statements the company filed with the SEC (10-K, 10-Q). Free cash flow = operating cash flow − capital expenditures; empty if the company does not report capex. “Quality vs sector”: 0 to 100, the average of its percentiles in ROE, operating margin, free-cash-flow margin, revenue and earnings growth and net debt / EBITDA (at least 3 needed) against companies in its sector above $300M. How each figure is calculated
Earnings quality and debt
- Operating cash flow ÷ net income (12 months)
- no datanot calculated with negative net income
- Debt due within 12 months
- no data
From the figures the company filed with the SEC. Cash flow over net income near or above 1 means earnings are collected in cash; far below, that part is accounting. Coverage says how many times operating income pays the latest fiscal year's interest. Maturities come from the debt note of the latest annual report, counted from its closing date. “No data” never means zero.
Insiders (Form 4)
10% owners who bought (6 m): 0
Open-market purchases, excluding 10b5-1 plans. Officers and directors only; joint filers of the same purchase count as one. 10% owners with no role are shown separately. 0 = nobody bought; “no data” = we do not have its Form 4 filings.
Each of the company's Form 4 filings, on EDGAR ↗Latest trades, with date and filing →
Above 5% (13D/13G)
Disclosed stakes, with their amendments. A filing is not always a purchase: there are also reductions and changes of filing entity.
This list may be incomplete: we hold 13D and 13G filings made since Dec 23, 2024. A holder above 5% that has not filed anything since then is not shown here.
Above 5% over time (13D/13G)
Each holder with its filings in order. History since December 2024.
This company filed no 8-K forms in the last year. Foreign companies listed in the US (ADRs) report material events on forms 6-K and 20-F, and ETFs and funds do not file 8-Ks. If it is a foreign company listed in the US through ADRs (American Depositary Receipts), what trades are bank-issued certificates that represent shares from its home market. See its filings on EDGAR ↗
Other Health Care stocks in managers' portfolios
Same sector and a similar number of concentrated managers holding them. It is a list to keep exploring, not a recommendation.
- Agios PharmaceuticalsAGIO · 4 managers
- DavitaDVA · 4 managers
- KardiganKARD · 4 managers
- MapLight TherapeuticsMPLT · 4 managers
- Anteris Technologies GlobalAVR · 5 managers
- Compass TherapeuticsCMPX · 5 managers